[go: up one dir, main page]

EP0984941A2 - Quinoline and acridine derivatives as antiarrhythmic agents - Google Patents

Quinoline and acridine derivatives as antiarrhythmic agents

Info

Publication number
EP0984941A2
EP0984941A2 EP98924480A EP98924480A EP0984941A2 EP 0984941 A2 EP0984941 A2 EP 0984941A2 EP 98924480 A EP98924480 A EP 98924480A EP 98924480 A EP98924480 A EP 98924480A EP 0984941 A2 EP0984941 A2 EP 0984941A2
Authority
EP
European Patent Office
Prior art keywords
compound
group
primary
ring
secondary amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98924480A
Other languages
German (de)
French (fr)
Inventor
Derek Terrar
Edward Gill
Mamas Mamas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Publication of EP0984941A2 publication Critical patent/EP0984941A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C07D219/12—Amino-alkylamino radicals attached in position 9

Definitions

  • This invention results from the discovery of a family of compounds which show potassium channel blocking activity and which are structurally quite different from previous compounds known to have this property. Some compounds have been modified by the attachment of known groups having calcium channel blocking activity, and properties of these modified compounds are reported.
  • the invention provides, for use as a potassium channel blocker, a compound comprising a planar electron-deficient ring structure of at least two fused 6-membered rings containing at least one ring N atom.
  • Ring structures of two or more fused 6-membered rings are generally planar or achiral as a result of having aromatic unsaturation. This ring structure may have substituents that extend out of the plane of the ring system; but comparable ring systems that are not planar do not appear to have potassium channel blocking activity.
  • Q is optionally substituted alkyl
  • Y is H, halogen, primary, secondary or tertiary amine, optionally substituted alkyl , alkoxy or perfluoroalkyl, nitro or a group -L-Z; or two adjacent Y may be joined together to form a carbocyclic ring,
  • L is a linker chain of 1 -20 C, N, O or S atoms
  • Z is a calcium channel blocker, and n is 1 to 4.
  • a primary or secondary amine group is attached to the ring structure at a position para to a ring N atom.
  • Particularly preferred compounds of this type have the formula
  • R is primary or secondary amine or a group -L-Z
  • Y and n are as previously defined.
  • Preferred compounds have a group -L-Z which provides calcium channel blocking activity These are included as new compounds within the scope of the invention.
  • L is -NH(CH 2 ) 3 N(CH 2 ) 2 - and Z is phenyl or 3,4-dimethoxyphenyl.
  • Such groups are well known and described in the literature. See R Mannhold et al, Archives of Pharmacology, 1978, 302 217-226.
  • the compounds are expected to be useful for the prophylaxis or therapy of arrhythmia, for which purpose they are expected to be injected into the blood stream. They will also be useful as experimental tools to separate components of the potassium current in a variety of tissues. These uses constitute further aspects of the invention.
  • Figure 1 shows the effect of 5mM E4031 on l ⁇ .
  • A. Mean data from 7 cells before (filled circles) and after (empty circles) exposure to E4031.
  • switch voltage clamp 36°C
  • Figure 14 illustrates the log(dose)-response curve of l KR and l Ca inhibition by GT96/1 ,2,3&4.
  • l Ca was activated by step depolarisations from -40mV to 0 mV for 200ms (switched voltage clamp).
  • I ⁇ was activated by step polarisations from -40mV to +40mV for 10-800ms (switched voltage clamp) and measured as outward tails upon repolarisation to -40mV; current at 40 ms was taken to represent l Kr (see Heath & Terrar, 1996, Experimental Physiology, 81 , p587-603).
  • the delayed rectifier potassium current (l ⁇ ) is one of the major time and voltage dependent outward potassium currents in heart cells, it plays an important role in the repolarisation of cardiac action potentials.
  • Two components of l ⁇ have been separated and can be distinguished by their differing kinetics and pharmacology.
  • the rapidly activating component (l Kr ) exhibits rapid activation, being maximal within 50ms and is sensitive to the class IN antiarrhythmic drug E4031.
  • the more slowly activating component (l ⁇ s ) exhibits a slower, sigmoidal activation and even at very long and very positive potentials it does not become maximally activated. This component is sensitive to the general anaesthetics propofol and thiopentone.
  • FIG. 1A illustrates that following exposure of guinea pig isolated ventricular heart cells to 5 ⁇ M E4031 , a reduction in l ⁇ was observed, especially l ⁇ activated by short pulses of less than 200ms. Since E4031 is reported to selectively block l Kr , the current remaining in the presence of E4031 represents l ⁇ s and in accordance with this, the drug-insensitive l ⁇ is slow to activate and exhibits a sigmoidal activation. Subtraction of the E4031 insensitive current from control current produced the E4031 -sensitive current, or l Kr ( Figure 1B), exhibiting a rapid activation, being maximal within 50ms.
  • Guinea-pig hearts were mounted on a Langendorff apparatus, and perfused through the aorta with a solution at pH 7.4, 36°C as described in Heath B M and Terrar D A, Experimental Physiology, Vol 81 , p 587-603 (1996). Ischaemia was induced by stopping the inflow of perfusing solution for 30 minutes. Arrhythmias were provoked following reperfusion. Arrhythmias were quantified by:-
  • the output of this device was proportional to the interval between beats so that a steady level reflected a steady rate and fluctuations in this level reflected disturbances in rhythm.
  • the possible effect of novel compounds on arrhythmias was tested by switching the inflow of the perfusion apparatus to a solution containing the compound of interest GT 96/4, at 10 "7 M. Reversibility of effect was tested by switching back to drug-free solution.
  • Arrhythmia was quantified from a recording of the intervals between heart contractions in such a manner that a large variation in rhythm gave rise to a large value (arbitrary units). Results are reported below.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compounds having formula (I) or (II) where R is primary or secondary amine or a group -L-Z, Y is H, halogen, alkyl, alkoxy, perfluoroalkyl, nitro or -L-Z, n is 1 to 4, L is a linker chain of 1-20 C, N, O or S atoms, and Z is a calcium channel blocker; have potassium channel blocking activity and are useful for the prophylaxis or therapy of arrhythmia.

Description

ANTIARRHYTHMIC AGENTS
As a result of the outcome of a cardiac arrhythmia suppression trial in 1989, the search for drugs controlling reentrant ventricular tacyarrhythmias and sudden death has focused on agents that prolong the cardiac action potential and refractoriness (i.e. drugs that possess class III antiarrhythmic action). The prototype class III antiarrhythmic drugs currently in clinical use are amiodarone and sotalol. However amiodarone has a complex pharmacological profile and its precise mechanism of action is unclear; and sotalol, in addition to prolonging action potential duration, is a β adenoreceptor antagonist that may cause cardiac depression and negative inotropism. Selective block of cardiac potassium current will prolong action potential duration and hence the refractory period, an effect believed to contribute to the antiarrhythmic actions of existing drugs derived from sotalol derivatives. However, prolongation of action potential duration in such a manner may be pro-arrhythmic under certain conditions occurring as a result of disturbances of calcium balance in the heart. In consequence, one group has sought to develop an antiarrhythmic agent that shows both calcium channel and potassium channel blocking activity (A Bril et al, J Pharmacol. Exp. Ther. 276 (2), 637-646 (1996)).
This invention results from the discovery of a family of compounds which show potassium channel blocking activity and which are structurally quite different from previous compounds known to have this property. Some compounds have been modified by the attachment of known groups having calcium channel blocking activity, and properties of these modified compounds are reported. The invention provides, for use as a potassium channel blocker, a compound comprising a planar electron-deficient ring structure of at least two fused 6-membered rings containing at least one ring N atom.
Ring structures of two or more fused 6-membered rings are generally planar or achiral as a result of having aromatic unsaturation. This ring structure may have substituents that extend out of the plane of the ring system; but comparable ring systems that are not planar do not appear to have potassium channel blocking activity.
The presence in the system of at least one ring N atom makes or tends to make the ring structure electron-deficient. But this effect may not be shown, or not sufficiently shown by the simple unsubstituted ring structure. The effect is greatly accentuated if the ring N atom is itself substituted. The effect is greatly accentuated by the presence, ortho or para to a ring N atom, of an electron-withdrawing substituent. Preferred compounds are based on quinoline and acridine.
On the fused ring structures of these compounds may be bonded substituents designed to perform various functions: to increase the electron deficiency of the ring structure; to provide calcium channel blocking activity; to enhance the lipophilic or hydrophilic properties; to provide a zero or positive or negative charge on the compound as a whole. Preferred compounds have the formula
where 1 ,2 or 3 of X1, X2, X3 and X4 are N or ≡N+-Q and each remaining X1, X2, X3 and X4 is ≡C-Y,
Q is optionally substituted alkyl,
Y is H, halogen, primary, secondary or tertiary amine, optionally substituted alkyl , alkoxy or perfluoroalkyl, nitro or a group -L-Z; or two adjacent Y may be joined together to form a carbocyclic ring,
L is a linker chain of 1 -20 C, N, O or S atoms,
Z is a calcium channel blocker, and n is 1 to 4.
Preferably a primary or secondary amine group is attached to the ring structure at a position para to a ring N atom. Particularly preferred compounds of this type have the formula
where R is primary or secondary amine or a group -L-Z,
Y and n are as previously defined.
Preferred compounds have a group -L-Z which provides calcium channel blocking activity These are included as new compounds within the scope of the invention. Preferably L is -NH(CH2)3N(CH2)2- and Z is phenyl or 3,4-dimethoxyphenyl. Such groups are well known and described in the literature. See R Mannhold et al, Archives of Pharmacology, 1978, 302 217-226. The compounds are expected to be useful for the prophylaxis or therapy of arrhythmia, for which purpose they are expected to be injected into the blood stream. They will also be useful as experimental tools to separate components of the potassium current in a variety of tissues. These uses constitute further aspects of the invention. Reference is directed to the accompanying drawings, in which Figures 1 -6, 8-12 and 14 are graphs of various effects against time, and Figures 7 and 13 show compound structures.
Figure 1 shows the effect of 5mM E4031 on lκ. A. Mean data from 7 cells before (filled circles) and after (empty circles) exposure to E4031. B. E4031 sensitive currents. Iκ was activated by step depolarisations from -40mV to +40mV for 10 to 800 ms and were measured as outward tails upon repolarisation to -40mV (switch voltage clamp; 36°C) in the presence of cytosolic BAPTA to suppress calcium transients. A similar protocol was adopted in all subsequent experiments where lκ was investigated (see Heath & Terrar, 1996, Experimental Physiology, 81 , p587-603).
Figure 14 illustrates the log(dose)-response curve of lKR and lCa inhibition by GT96/1 ,2,3&4. lCa was activated by step depolarisations from -40mV to 0 mV for 200ms (switched voltage clamp). Iκ was activated by step polarisations from -40mV to +40mV for 10-800ms (switched voltage clamp) and measured as outward tails upon repolarisation to -40mV; current at 40 ms was taken to represent lKr (see Heath & Terrar, 1996, Experimental Physiology, 81 , p587-603).
EXPERIMENTAL The delayed rectifier potassium current (lκ) is one of the major time and voltage dependent outward potassium currents in heart cells, it plays an important role in the repolarisation of cardiac action potentials. Two components of lκ have been separated and can be distinguished by their differing kinetics and pharmacology. The rapidly activating component (lKr) exhibits rapid activation, being maximal within 50ms and is sensitive to the class IN antiarrhythmic drug E4031. The more slowly activating component (lκs) exhibits a slower, sigmoidal activation and even at very long and very positive potentials it does not become maximally activated. This component is sensitive to the general anaesthetics propofol and thiopentone. EXAMPLE 1
Using the known class III antiarrhythmic drug E4031 which is believed to be a selective blocker of lKr, the two components of the delayed rectifier potassium current can be separated. Figure 1A illustrates that following exposure of guinea pig isolated ventricular heart cells to 5μM E4031 , a reduction in lκ was observed, especially lκ activated by short pulses of less than 200ms. Since E4031 is reported to selectively block lKr, the current remaining in the presence of E4031 represents lκs and in accordance with this, the drug-insensitive lκ is slow to activate and exhibits a sigmoidal activation. Subtraction of the E4031 insensitive current from control current produced the E4031 -sensitive current, or lKr (Figure 1B), exhibiting a rapid activation, being maximal within 50ms.
The actions of E4031 on lκ illustrated in Figure 1A are representative of a typical response to a selective IKr blocker, and similar actions on lκ were recorded with the novel lKr blockers of this invention. The initial experiments which led to the characterisation of the novel chemical group exhibiting lKr blocking activity followed from the observations that exposure of guinea pig isolated ventricular heart cells to methylene blue (10 μM), an inhibitor of the cytosolic enzyme guanylate cyclase, enhanced cell contraction amplitude (Figure 2A), with an associated increase in action potential duration. These actions appeared not to be related to the inhibition of guanylate cyclase activity since exposure of cells to a structurally dissimilar guanylate cyclase inhibitor, LY83583 (10 μM) did not produce such responses (Figure 2B). The prolongation of action potential duration and hence increase in cell contractility observed following exposure to methylene blue was not associated with effects on either L-type calcium currents (Figure 3) or inwardly rectifying potassium currents (Figure 4). In contrast, a decline in the rapidly activating component of the delayed rectifier potassium current was observed following exposure to 10 μM methylene blue (Figure 5). The structurally dissimilar guanylate cyclase inhibitor LY83583 (10 μM) had no effects on lKr (Figure 6), it therefore seems likely that methylene blue inhibits lKr through a direct action on the channel rather than through inhibition of guanylate cyclase activity. Further support for such a view is that compounds such as quinacrine (Figure 7), chloroquine (Figure 7) and 9-aminoacridine (Figure 7), which do not exhibit guanylate cyclase inhibiting activity, but possess a flat planar electron deficient ring structure similar to that of methylene blue (Figure 7) also exhibit potent lKr blocking activity (Figure 8). In a separate set of experiments the inventors have also investigated the lκs blocking activity of one of these compounds,
9-aminoacridine which appears to be negligible at 10 μM, demonstrating that these compounds are selective for lKr. In the next set of experiments the inventors investigated whether the positive charge and/or the flat planar structure of such compounds is required for lKr blocking activity. Acridine hydrochloride (Figure 7) possesses a flat planar electroneutral ring structure but did not exhibit lKr blocking activity (Figure 9). In contrast the structurally similar methylacridine sulphonate (Figure 7) which possesses a weakly positively charged flat planar ring structure exhibited lKr blocking activity (Figure 10); hence it appears that an electron deficient ring structure is required for lKr blocking activity. 9-aminotetrahydroacridine (Figure 7) has 2 unsaturated electron deficient rings which lie in the same plane (although the saturated ring introduces a kink at the end of the compound) and this exhibits lKr blocking activity (Figure 11). In contrast 1 ,2,3,4-tetrahydroquinoline (Figure 7) does not possess a flat planar structure and although it is electron deficient it does not exhibit lKr blocking activity (Figure 12); hence it appears that at least 2 rings must lie in a plane and that this flat planar portion of molecule must be electron deficient for a compound to exhibit lKr blocking activity. EXAMPLE 2
In addition the inventors have synthesised a novel set of compounds which incorporate both the chemical group exhibiting lKr blocking activity and an additional chemical group conferring calcium channel blocking activity (Figure 13). Both the calcium channel and potassium channel blocking activity has been investigated in these newly synthesised compounds (Figure 14). Compound GT96/4 appears to show the greatest difference in potency between block of lKr and of calcium channels.
Antiarrhythmic Properties of GT 96/4
Guinea-pig hearts were mounted on a Langendorff apparatus, and perfused through the aorta with a solution at pH 7.4, 36°C as described in Heath B M and Terrar D A, Experimental Physiology, Vol 81 , p 587-603 (1996). Ischaemia was induced by stopping the inflow of perfusing solution for 30 minutes. Arrhythmias were provoked following reperfusion. Arrhythmias were quantified by:-
• taking a signal from a tension transducer (attached to the heart by a hook at its apex and therefore measuring ventricular contraction), and
• feeding this signal to a device which measured the interval between contractions (the reciprocal of heart rate).
The output of this device was proportional to the interval between beats so that a steady level reflected a steady rate and fluctuations in this level reflected disturbances in rhythm. The possible effect of novel compounds on arrhythmias was tested by switching the inflow of the perfusion apparatus to a solution containing the compound of interest GT 96/4, at 10"7M. Reversibility of effect was tested by switching back to drug-free solution. Arrhythmia was quantified from a recording of the intervals between heart contractions in such a manner that a large variation in rhythm gave rise to a large value (arbitrary units). Results are reported below.

Claims

1. For use as a potassium channel blocker, a compound comprising a planar electron-deficient ring structure of at least two fused 6- membered rings containing at least one ring N atom.
2. A compound as claimed in claim 1 having the formula
where 1 ,2 or 3 of X1, X2, X3 and X4 are N or ΓëíN+-Q and each remaining X1, X2, X3 and X4 is ΓëíC-Y,
Q is optionally substituted alkyl, Y is H, halogen, primary, secondary or tertiary amine, optionally substituted alkyl , alkoxy or perfluoroalkyl, nitro or a group -L-Z; or two adjacent Y may be joined together to form a carbocyclic ring,
L is a linker chain of 1-20 C, N, O or S atoms,
Z is a calcium channel blocker, and n is 1 to 4.
3. A compound as claimed in claim 1 or claim 2, wherein a primary or secondary amine group is attached to the ring structure at a position para to a ring N atom.
4. A compound as claimed in claim 3 having the formula
where R is primary or secondary amine or a group -L-Z,
Y and n are as previously defined.
5. A compound as claimed in claim 4, wherein Y is H, chloro, primary or secondary amine or methoxy or the group -L-Z, and L is a linker chain of 1-20 carbon atoms, optionally including one or more O, N or S atoms.
6. A compound as claimed in claim 4 or claim 5, wherein R is -L-Z..
7. A compound as claimed in any one of claims 2 to 6, wherein L is -NH(CH2)3N(CH3)(CH2)2- and Z is phenyl or 3,4-dimethoxyphenyl.
8. A compound having the formula:
where 1 ,2 or 3 of X1, X2, X3 and X4 are N or ΓëíN+-Q and each remaining X1, X2, X3 and X4 is =C-Y,
Q is optionally substituted alkyl,
Y is H, halogen, primary, secondary or tertiary amine, optionally substituted alkyl , alkoxy or perfluoroalkyl, nitro or a group -L-Z; or two adjacent Y may be joined together to form a carbocyclic ring, L is a linker chain of 1-20 C, N, O or S atoms,
Z is a calcium channel blocker, and n is 1 to 4, provided that at least one group -L-Z is present.
9. A compound as claimed in claim 8, wherein a primary or secondary amine group is attached to the ring structure at a position para to a ring N atom.
10. A compound as claimed in claim 8, having the formula
where R is primary or secondary amine or a group -L-Z, Y and n are as previously defined.
11. A compound as claimed in claim 10, wherein Y is H, chloro, primary or secondary amine or methoxy or the group -L-Z, and L is a linker chain of 1-20 carbon atoms, optionally including one or more O, N or S atoms.
12. A compound as claimed in claim 10 or claim 11 , wherein R is -L-Z.
13. A compound as claimed in any one of claims 8 to 12, where L is -NH(CH2)3N(CH3)(CH2)2- and Z is phenyl or 3,4-dimethoxyphenol.
14. A method of preparing an anti-arrhythmic agent, which method comprises bringing a compound as claimed in any one of claims 1 to 12 into a form suitable for administration.
EP98924480A 1997-05-30 1998-05-29 Quinoline and acridine derivatives as antiarrhythmic agents Withdrawn EP0984941A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9711220.5A GB9711220D0 (en) 1997-05-30 1997-05-30 Antiarrhythmic agents
GB9711220 1997-05-30
PCT/GB1998/001579 WO1998054148A2 (en) 1997-05-30 1998-05-29 Quinoline and acridine derivatives as antiarrhythmic agents

Publications (1)

Publication Number Publication Date
EP0984941A2 true EP0984941A2 (en) 2000-03-15

Family

ID=10813337

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98924480A Withdrawn EP0984941A2 (en) 1997-05-30 1998-05-29 Quinoline and acridine derivatives as antiarrhythmic agents

Country Status (3)

Country Link
EP (1) EP0984941A2 (en)
GB (1) GB9711220D0 (en)
WO (1) WO1998054148A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012154879A2 (en) 2011-05-09 2012-11-15 Van Andel Research Institute Autophagy inhibitors
CN115947683B (en) * 2022-12-29 2025-08-05 湖南工程学院 A method for synthesizing tetrahydroquinoline and its derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957791A (en) * 1972-09-25 1976-05-18 Sandoz, Inc. Hydroxyalkyl-piperazino-quinoline nitrates
GB8609331D0 (en) * 1986-04-16 1986-05-21 Pfizer Ltd Anti-arrythmia agents
US4956382A (en) * 1987-02-07 1990-09-11 Pfizer Inc. Sulfonamide anti-arrhythmic agents
EP0446604A3 (en) * 1990-03-16 1992-02-19 American Cyanamid Company Pyridine and related aza heterocycle derivatives as cardiovascular agents
FR2681598B1 (en) * 1991-09-24 1993-11-12 Roussel Uclaf NOVEL DECAHYDROQUINOLEIN DERIVATIVES, THEIR PREPARATION PROCESS, THE PREPARATION INTERMEDIATES, THEIR APPLICATION AS MEDICAMENTS AND THE COMPOSITIONS CONTAINING THEM.
JPH083144A (en) * 1994-06-21 1996-01-09 Chugai Pharmaceut Co Ltd Quinazoline and quinoline derivative
KR960007566A (en) * 1994-08-19 1996-03-22 김정규 Novel quinolylamine derivatives, methods for their preparation and use as antiarrhythmics
NZ325248A (en) * 1995-12-23 1999-09-29 Pfizer Res & Dev Quinoline and quinazoline compounds useful in therapy
NZ329200A (en) * 1996-12-16 1999-05-28 Hoechst Ag Sulphonamide substituted quinazoline, isoquinoline, quinoline or benzo[1,3-]oxazine derivatives and medicaments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9854148A3 *

Also Published As

Publication number Publication date
WO1998054148A3 (en) 1999-03-04
WO1998054148A2 (en) 1998-12-03
GB9711220D0 (en) 1997-07-23

Similar Documents

Publication Publication Date Title
CA2059363A1 (en) Benzo¬5,6|cyclohepta¬1,2-b|pyridine derivatives and antiallergic agents comprising same
TR199802202T2 (en) �substituted indezole derivatives; tumor necrosis factor (TNF) production.
FI882813A0 (en) PYRAZOLOPYRIDINFOERENING OCH FOERFARANDE FOER DESS FRAMSTAELLNING.
KR950702979A (en) Arylidene and heteroarylidene oxindole derivatives as tyrosine kinase inhibitors
ATE152443T1 (en) ANILIDE DERIVATIVES
AR036107A1 (en) DERIVATIVES OF 6-PHENYLPIRROLPIRIMIDINDIONA, ANTAGONIST OF ADENOSINE A2 RECEPTORS, PARTICULARLY OF SUBTIPO A2, APPLICATION IN THE PREVENTION OF THE DEGRANULATION OF MASTOCITS; PHARMACEUTICAL COMPOSITIONS FORMULATED WITH SUCH COMPOUNDS AND THE SAME USE IN THE PREPARATION OF MEDIUM
JPS6470414A (en) Dihydropyridine-containing continuous medicine
RU93004675A (en) 1,2,4-Oxadiazolyl-phenoxyalkylisoxazoles, their use as antiviral agents, pharmaceutical composition
RU92016592A (en) HIV INHIBITING BENZOLACETAMIDE DERIVATIVES
NO163855C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE ARYLYCYLOBUTYLALKYLAMINES.
ES8500247A1 (en) A PROCEDURE FOR THE PREPARATION OF AN OPTICAL ISOMER IN ITS FORM (-) OF A TRIAZINE DERIVATIVE.
WO1998054148A2 (en) Quinoline and acridine derivatives as antiarrhythmic agents
EP0211272A3 (en) Azo compound and colored composition containing same
EP0206616A3 (en) Quinolones having antihypertensive activity
EP0351255A3 (en) Derivatives of û2-(4-piperidinyl)methyl¨-1,2,3,4-tetrahydroisoquinoline, their preparation and their use in therapy
KR880012594A (en) Benzo- and thieno-3,4-dihydro-pyridine derivatives, methods for their preparation and pharmaceutical compositions containing these compounds
KR900001691A (en) Pyridazinone derivatives
ES8308325A1 (en) "PROCEDURE FOR THE PREPARATION OF BENZOTRIAZOLES".
Schächtele et al. Effect of Ca2+ entry blockers on myosin light-chain kinase and protein kinase C
MX9304403A (en) PHARMACOLOGICALLY ACTIVE DERIVATIVES OF Ó- (TERTIARY AMINOMETHYL) -BENCENMETANOL
ATE50248T1 (en) AN IMIDAZOLIDINETRIONE DERIVATIVE OR A PHARMACEUTICAL COMPOSITION CONTAINING ITS PHARMACEUTICALLY ACCEPTABLE SALTS.
IE44886B1 (en) Quinoline carboxylic acid esters
HJORT et al. Relative pharmacological effects of 1-methyl-3, 4-dihydro-and 1-methyl-1, 2, 3, 4-tetrahydroisoquinoline derivatives
ES472591A1 (en) Anti-inflammatory 1-phenylethanolamine derivatives, pharmaceutical compositions thereof and processes for their manufacture.
AU615883B2 (en) Pharmaceutical composition for use against hypertension and congestive heart failure

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991125

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20021203